Sanuj Ravindran
Sanuj Ravindran, M.D., is the CEO of Simcha Therapeutics, a New Haven clinical-stage immunobiology company turning a once-overlooked immune molecule, interleukin-18, into a cancer weapon. A board-certified physician who spent a decade as a venture capitalist before becoming a serial biotech company-builder, Ravindran took the helm in 2022 to push ST-067, a decoy-resistant IL-18 designed to slip past the body's own off-switch and reawaken the immune system inside tumors. He has run drug programs across oncology and rare disease, structured more than $2 billion in deals, and bets his career on therapies that promise more than incremental gains.
sanuj ravindransimcha therapeuticsceobiotechimmunotherapycancer immunology